[1] Huang YS.Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury[J]. J Chin Med Assoc, 2014, 77(4):169-173. [2] 刘诚诚,金海霞,徐建等. 结核病患者N-乙酰基转移酶2基因型与异烟肼血药浓度关系的研究[J]. 中国防痨杂志, 2013, (03):179-182. [3] Chen B, Li JH, Xu YM, et al.The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients[J]. Clin Chim Acta, 2006, 365(1-2):104-108. [4] Fukino K, Sasaki Y, Hirai S, et al.Effects of N-acety–ltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients[J]. J Toxicol Sci, 2008, 33(2):187-195. [5] Chen B, Cai X, Li J.Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects[J]. Drug Metabol Drug Interact, 2011, 26(3):113-118. [6] Sabbagh A, Darlu P, Crouau-Roy B, et al.Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey[J]. Plos One, 2011, 6(4):e18507. [7] Lin HJ, Han CY, Lin BK, et al.Ethnic Distribution of Slow Acetylator Mutations in the Polymorphic N-Acetyltransferase (NAT2) Gene[J]. Pharmacogenetics, 1994, 4(3):125-134. [8] Cascorbi I, Brockmoller J, Mrozikiewicz PM, et al.Arylamine N-acetyltransferase activity in man[J]. Drug Metab Rev, 1999, 31(2):489-502. [9] Meyer UA, Zanger UM.Molecular mechanisms of genetic polymorphisms of drug metabolism[J]. Annu Rev Pharmacol, 1997, 37(6):269-296. [10] Kiyohara C, Washio M, Horiuchi T, et al.Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population[J]. Lupus, 2009, 18(7):630-638. [11] Xie HG, Xu ZH, OuYang DS, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations[J]. Pharmacogenetics, 1997, 7(6):503-514. [12] Ohno M, Yamaguchi I, Yamamoto I, et al.Slow N-acety-ltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity[J]. Int J Tuberc Lung Dis, 2000, 4(3):256-261. [13] Hiratsuka M, Kishikawa Y, Takekuma Y, et al.Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients[J]. Drug Metab Pharmacokinet, 2002, 17(4):357-362. [14] Cai Y, Yi J, Zhou C, et al.Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis[J]. PLoS One, 2012, 7(10):e47769. [15] Du H, Chen X, Fang Y, et al.Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis[J]. Mol Biol Rep, 2013, 40(5):3591-3596. [16] Donald PR, Sirgel FA, Venter A, et al.The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid[J]. Clin Infect Dis, 2004, 39(10):1425-1430. [17] Donald PR, Parkin DP, Seifart HI, et al.The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid[J]. Eur J Clin Pharmacol,2007, 63(7):633-639. [18] Kubota R, Ohno M, Hasunuma T, et al.Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2[J]. Eur J Clin Pharmacol, 2007, 63(10):927-933. [19] Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al.Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?[J]. Antimicrob Agents Chemother, 2005, 49(5):1733-1738. [20] Azuma J, Ohno M, Kubota R, et al.NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy[J]. Eur J Clin Pharmacol, 2013, 69(5):1091-1101. |